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Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased
resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-
producing organisms are associated with a higher morbidity and mortality and greater ﬁscal burden. Coupled with increasing
prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, these enzymes represent a clear and
present danger to public health. This article aims to give an overview of the current situation regarding ESBLs, with a focus on the
epidemiology and management of such infections.
1.IntroductionandDeﬁnition
Critically ill patients are especially prone to infection, and
the nature and epidemiology of causative agents can vary
tremendously. In particular, drug-resistant pathogens are
of a major concern, as they carry a higher morbidity and
mortality and are more diﬃcult to identify by routine
laboratory assays, which can lead to a delay in diagnosis
andinstitutionofappropriateantimicrobialtherapy.Thereis
also a growing concern regarding the lack of new antibiotics
[1]especiallyformultidrug-resistantGram-negativebacteria
which produce extended spectrum β-lactamases (ESBLs).
In June 2010, the Infectious Diseases Society of America
gave testimony before the House Committee on Energy and
Commerce Subcommittee on Health, on the critical need
for stewardship of antimicrobials and the urgent necessity of
research and development into newer therapies.
β-lactamases are hydrolytic enzymes which cleave the β-
lactam ring and are the primary mechanism of conferring
bacterialresistancetoβ-lactamantibiotics,suchaspenicillins
and cephalosporins.
Theseenzymescanbecarriedonbacterialchromosomes,
that is, inherent to the organism, or may be plasmid-media-
tedwiththepotentialtomovebetweenbacterialpopulations.
This has clear implications regarding spread of infection and
infection control, which will be discussed later.
ESBLs are primarily produced by the Enterobacteriaceae
family of Gram-negative organisms, in particular Klebsiella
pneumonia and Escherichia coli [2, 3]. They are also pro-
ducedbynonfermentativeGram-negativeorganisms,suchas
Acinetobacter baumannii and Pseudomonas aeruginosa [4].
The original method of β-lactamase categorisation is the
Ambler classiﬁcation [5] which orders the enzymes into 4
classes (A, B, C, and D) based on molecular structure.
ESBLs are Class A β-lactamases and may be deﬁned as
plasmid-mediated enzymes that hydrolyse oxyimino-cephal-
osporins, and monobactams but not cephamycins or carba-
penems [6]. They are inhibited in vitro by clavulanate [2].
There are various genotypes of ESBLs. Of these, the most
common are the SHV, TEM, and CTX-M types [7]. Other
clinically important types include VEB, PER, BEL-1, BES-1,
SFO-1, TLA, and IBC [4].
In 1995, Bush et al. devised a classiﬁcation of β-lacta-
mases based upon their functional characteristics and sub-
strate proﬁle, a classiﬁcation which is widely used [8].
The enzymes are divided into three major groups: group
1 cephalosporinases which are not inhibited by clavulanic
acid, the larger group 2 broad spectrum enzymes which are2 Critical Care Research and Practice
Table 1
Bush-Jacoby-Medeiros
Group
Molecular class
(Ambler) Preferred substrates Representative enzymes Resistance or susceptibility to
β-lactamase inhibitors
1 C Cephalosporins AmpC Resistant
2b A Penicillins, Cephalosporins TEM, SHV Susceptible
2be A
Penicillins,
extended-spectrum
cephalosporins,
monobactams
TEM, SHV Susceptible
2d D Penicillins, cloxacillin OXA Resistant
2e A Cephalosporins
Inducible
cephalosporinases from
Proteus vulgaris
Susceptible
2f A Penicillins, cephalosporins,
carbapenems
NMC-A from Enterobacter
cloacae Resistant
3B Most β-lactams including
carbapenems
L1 from Stenotrophomonas
maltophilia Resistant
Amended from original Bush-Jacoby-Medeiros classiﬁcation scheme for bacterial β-lactamases.
generally inhibited by clavulanic acid (except for the 2d and
2f groups) and the group 3 metallo-β-lactamases.
The main points are illustrated in Table 1.
Most ESBLs are assigned to group 2be, that is, hydrolyse
penicillins,cephalosproins,andmonobactams,andinhibited
byclavulanicacid(aspertheAmblerclassiﬁcation).Itshould
be noted that the CTX-M genotype was not classiﬁed in this
original schemata but still fulﬁls the above criteria for group
2be enzymes.
2. Epidemiology
When ESBLs were ﬁrst recognized in the early 1980s, they
were found to be point mutations of the TEM and SHV
broad spectrum enzymes, which resulted in resistance to
the β-lactam class of antibiotic [9, 10]. The mutations in
the genes results in these enzymes having high catalytic
capabilities for β-lactams due to low Km values (i.e., high
aﬃnity) for the compounds [11].
They have become a major cause of hospital-acquired
infection, particularly in the intensive care unit (ICU), with
the majority of ESBL producers being isolated from critical
care patients [3, 12].
TEM and SHV-types have been recognized across the
world with over 100 mutations being reported as oﬀering
resistancetotheextendedspectrumcephalosporins.Thiswas
driven by the heavy use of such antibiotics [13].
Since the start of the 21st century, it has becoming
increasingly evident that a shift in the genotypic makeup of
ESBLs is taking place.
The CTX-M genotype, originating from chromosomally
encoded enzymes of the Kluyvera spp, has risen in promi-
nence especially in E. coli and K. pneumonia [3, 12, 13]. It is
believed the genes were then conjugated onto plasmids from
where they were transferred to pathogenic species, with the
ability to move between diﬀerent bacterial populations [14].
Table 2
Community onset Hospital onset,
particularly ITU
Organism E. coli Klebsiella spp
Type of ESBL CTX-M SHV,TEM
Type of infection
Usually UTIs, but also
bacteraemia and GI
infection
Bacteraemia,
intra-abdominal, and
respiratory and urinary
infection
Molecular
epidemiology
Isolates not always
related
Isolates usually related,
that is, outbreak
Table 3
Factor Odds ratio (95% CIs)
ICU admission 1.67 (1.16–2.40)
Renal failure 1.92 (1.21–3.04)
Burns 2.78 (1.92–4.01)
TPN 1.72 (1.18–2.49)
Urinary catheter 1.88 (1.25–2.83)
3rd Gen cephalosporin 2.99 (1.6–4.0)
The CTX-M enzymes appear to have a greater ability to
spread and cause outbreaks.
There are over 50 variants of CTX-M to date, and they
have been associated with numerous outbreaks of infections
both in hospitals and in the community, particularly in
urinary E. coli isolates in a nonhospital setting [3, 13].
A paper two years ago in the Lancet Infectious Diseases
described some key characteristics between hospital and
nosocomial infections with ESBLs [15].
This includes the informations mentioned in Table 2.
Risk factors for acquiring hospital associated ESBL infec-
tion [16] include the informations mentioned in Table 3.Critical Care Research and Practice 3
Risk factors for acquiring community-associated ESBL
infection [17] include:
(i) recurrent UTI,
(ii) previous antibiotic usage,
(iii) diabetes mellitus,
(iv) prior instrumentation to urinary tract,
(v) female sex,
(vi) age (over 65 years).
Data from the last 10 years establishes CTX-M genotype as
the predominant ESBL in Europe and East Asia, as will be
discussed below.
Clearly, the rise of multidrug-resistant organisms in the
community is of a huge public health concern.
2.1. Global Epidemiology. The prevalence of bacteria pro-
ducing ESBLs varies worldwide, with reports from North
America, South America, Europe, Africa, and Asia [14].
Data from the Tigecycline Evaluation and Surveillance Trial
(TEST) global surveillance database shows the rate of ESBL
production was highest among the K. pneumoniae isolates
collected in Latin America, followed by Asia/Paciﬁc Rim,
Europe, and North America (44.0%, 22.4%, 13.3%, and
7.5%, resp.)[3, 18].
2.2. USA. First reports of ESBLs in the USA in the late 1980s
were reported with TEM-type [19] and the major enzymes
appear to be the TEM and SHV types, with a minimal
appearance of CTX-M types [20]. Both the prevalence of
ESBLs and types involved found in the USA are in stark
contrast to the epidemiology seen in the rest of the world,
including Canada, where outbreaks of CTX-M producing K.
pneumoniae have been seen [21].
The juxtaposition of the USA and Canada would suggest
the spread of CTX-M types south of the border is a
real threat. Indeed a recent report draws attention to the
emergence of CTX-M types in a US health care system [22].
Data from several surveillance surveys conducted in the
USA provides a broader picture of prevalence rates [20].
The National Nosocomial Infections Surveillance Sys-
tems report issued in October 2004 from the CDC compared
dataonnosocomialinfectionsfromseveralcentresacrossthe
United States [23]. It looked at ICU and non-ICU settings.
Rates of Kp n e u m o n i aresistant to third generation
cephalosporins (i.e., presumed ESBL producers) increased
by 43% in 2003, compared with data from 1998 to 2002.
Resistant E. coli rates were unchanged. When resistant rates
were pooled across all ITUs (to include adult, paediatric,
and cardiothoracic), the percentage of resistant Kp n e u m o n i a
accounted for 6.2% of isolates, whereas cephalosporin resis-
tant E. coli was lower at 1.3% of all Ec o l iisolates from ITU
patients. This compared to 5.8% and 1.5%, respectively, in
non-ITU settings.
In the late 1990s, the SENTRY study analysed isolates
overa12-monthperiodinthelate1990sandshowedahigher
percentage of ESBLs in K. pneumoniae strains in US centres
versus Canadian (7.6% versus 4.9%), with E. coli producing
ESBLs demonstrating no signiﬁcant diﬀerence [24].
Interestingly More Recent Data from the MYSTIC
programme (which looked at ESBL production from K.
pneumoniae and E. coli isolates over a 5-year period from
1999–2004) showed a low level of ESBL prevalence, with less
than 1.5% of E. coli strains producing ESBLS from 2001–
2004. A similarly low level was seen in Klebsiella spp over
the same time period, 2.4%–4.4% of strains producing the
enzymes [25].
T h e s el o wn u m b e r sa r ef u r t h e rc o r r o b o r a t e db yd a t a
from the CDC which looked mainly at hospital acquired
infections, with ESBLs contributing to 0.5%–1% of hospital
acquired infections [26].
2.3. Europe. In Europe, ESBL-producing Enterobacteriaceae
has been spreading at an alarming rate. Although there
is extensive diﬀerence between European countries, almost
every European country has experienced outbreaks with
ESBL-producing organisms [2].
T h eﬁ r s ti s o l a t e sw e r eo r i g i n a l l yd e t e c t e di nG e r m a n y[ 9]
and the UK; however, the ﬁrst large outbreak was seen in
France, where over 50 patients in an intensive care unit were
aﬀected with spread to other wards in the hospital [27].
During the 1980s and 1990s, TEM and SHV were the
predominantESBLtype.Theywerealmostexclusivelyhospi-
tal acquired infections and were associated with nosocomial
outbreaks, particularly in the ICU [28]. This role of the ICU
as a source of ESBL outbreak is commonly recognized as part
of the epidemiology of these organisms [3, 12].
Data from the European Antibiotic Resistance Surveil-
lance System conﬁrms the increasing prevalence of ESBLS
across Europe (see Figure 1).
Interestingly, there has been a slight fall in the number
of K. pneumoniae producing ESBL in Western Europe, likely
due to enhanced infection control practices and antimicro-
bial stewardship [29] .H o w e v e r ,t h i si sn o tt r u ef o rE a s t e r n
Europe, where numbers of resistant isolates appear to rising
[30]. According to the annual epidemiological report on
communicable diseases in Europe 2010 [31], E. coli showed
a Europe wide increase in resistance to all antibiotics under
surveillance.
The striking proliferation of the CTX-M enzymes has
resulted in a change in the distribution of ESBL types across
Europe; currently, CTX-M and TEM are the main types
[32]. In addition, community-acquired ESBL producing
organisms causing urinary tract infections, especially E. coli,
are showing a worrying rise in numbers [28].
It has been consistently shown that rate of ESBLs in
Europe is higher of that in the USA but lower than in Latin
America and Asia.
2.4. South America. R a t e so fE S B L si nS o u t hA m e r i c ar a n k
amongst the highest in the world, with CTX-M dominant.
Surveillance data reveal alarmingly high prevalence rates,
with Klebsiella isolates producing ESBLs from Latin America
ranging from 45% to 51% [24, 33].
Similarly, high rates are seen amongst E. coli isolates in
Latin America ranging from 8.5% to 18% [33].
Ther ear eman yr easonsast owh ypr evalenc erat esshould
be so high in this part of the world. Certainly, there is ample4 Critical Care Research and Practice
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evidence to suggest the spread of ESBL infections is higher in
resource poor countries [34, 35].
This could be due to poorer social and economic situa-
tions, hospital overcrowding, lack of antimicrobial steward-
ship and excessive over the counter antibiotic usage and un-
dersupported infection control practices [36].
2.5. Asia. In Asia, high rates of ESBL producing Enterobac-
teriaceae are seen.
This was ﬁrst highlighted by the SENTRY antimicrobial
surveillance programme 1998-1999 [37]; data prior to this is
lacking. Clearly over such a large geographical area, a large
variation is seen in prevalence rates and genotype of ESBL.
For example, in China, the incidence of ESBL production
from E.coli isolates ranged from13%–15%, witheven higher
rates amongst Klebsiella (>20%, with one centre reporting
over 60%) [37].
The paucity of data prior to the late 1990s makes it
diﬃcult to ascertain the genotypic makeup of the ESBL
producers during that time. The ﬁrst reports from Japan
and Taiwan suggest the SHV type played a key role early on
but, just like in mainland Europe, the rise of the CTX-M
genotype has made it the preeminent enzyme, with national
and regional variations [38].
2.6. Africa. In comparison with the rest of the world, there
is generally a lack of comprehensive data regarding ESBL
producingEnterobacteriaceaeinAfricancountries.However,
there is suﬃcient evidence to highlight the prevalence of
ESBLs in Africa.
It is recognized that Egypt has an extremely high rate of
ESBL producers, with up to 70% of isolates producing the
enzyme [39].
One survey compared data from Egypt, Lebanon, Saudi
Arabia, and South Africa, and Egypt was found to have the
highest rates of ESBLs [40].
Again, the CTX-M genotype appears to be the most
common type in North Africa [41]. There have also been
reports of CTX-M K. pneumoniae in Kenya [42]a n dS H V
and TEM—types in South Africa [43].
The high rate of ESBL producers in the developing world
is clearly worrying; lack of funds for eﬀective infection
control and limited access to eﬀective antimicrobials has
clear implications with regards to curbing the morbidity and
mortality associated with these infections.
3. ClinicalImplications
There is no doubt that ESBL-producing organisms are of
enormous clinical and microbiological signiﬁcance.
Such bacteria are associated with severe infections such
as bacteraemias, intra-abdominal infection, urinary tract
infections(particularlyinthecommunitysetting),andrespi-
ratory tract infections [15].
They inactivate cephalosporins, which are often used in
treating the septic patient in a variety of clinical settings.
Therefore, this often renders empiric antibiotic treatment
ineﬀective. The delay in laboratory diagnosis and time to
appropriate antibiotic therapy has been strongly linked to an
increased mortality in these cases [44, 45].
Therefore, it is of paramount importance that local
surveillance data of prominent infective pathogens is closely
monitored.
Aspreviouslymentioned,manyESBLgeneshavethepro-
pensity to jump between organisms, thus leading to out-
breaks of infection if this occurs in an easily transmissible
pathogen.
It is also known that organisms producing ESBLs also
have the ready capacity to acquire resistance to other antimi-
crobial classes such as the quinolones, tetracyclines, cotri-
moxazole, trimethoprim, and aminoglycosides, which fur-
ther limits therapeutic options [12, 46–48].Critical Care Research and Practice 5
CAZ
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Double disc testing
Figure 2:S ynergyisseenasane xpansionofthec ephalosporinz one
adjacent to the clavulanate containing disc CAZ—good substrate
forTEMandSHV’s,CTX—GoodforCTX-MESBLs.Theorganism
may appear resistant to 3rd-generation cephs, but susceptibility is
restored by the presence of clavulanate.
The mechanism behind this multiresistance phenome-
nonisgenetic;thegeneencodingforresistanceforbothESBL
andotherclasses(e.g.quinolones)areoftenassociatedonthe
same mobile DNA element (plasmid) [28]. The propagation
of this plasmid during conjugation leads to development of
multidrug resistance in previously sensitive organisms.
4.LaboratoryDiagnosis
ThelaboratorydiagnosisofESBL-producingbacteriaiscom-
plex and the intricacies are beyond the scope of this paper.
Essentially, most clinical diagnostic laboratories detect
ESBL producers by phenotypic tests, which require a screen-
ing step followed by conﬁrmation.
The screening test is based on testing the organism
for resistance to an indicator cephalosporin. Cefpodoxime
is commonly used as it is hydrolysed by TEM, SHV, and
CTX-M types, but other cephalosporins such as cefotaxime,
ceftriaxone, and ceftazidime are also used [49].
To conﬁrm the presence of an ESBL, synergy between
the indicator cephalosporin and clavulanic acid needs to be
demonstrated (ESBLs are inhibited by clavulanic acid) [49].
There are a variety of commercial tools available to
do this, including double disc synergy, combination disc
method, and speciﬁc ESBL E-tests [49, 50] (see Figures 2 and
3).
However, if the isolate produces an additional AmpC or
metallo-β-lactamase (which are not inhibited by clavulanic
acid), these methods will lose their sensitivity [50].
Both screening and conﬁrming the presence of an
ESBL producer can be technically diﬃcult, and it is time
consuming.Thiscanbeasigniﬁcantclinicalproblem,astime
to appropriate antibiotic is crucial in the management of a
septic patient.
Reference laboratories can test for genes encoding ESBLs
by molecular analysis, primarily polymerase chain reaction
ampliﬁcation of speciﬁc sequences. This is usually reserved
for epidemiological purposes, as it identiﬁes the particular
genotype of ESBL [15].
Newer technologies such as the molecular techniques
above and modiﬁcations of mass spectrometry (matrix-
assisted light desorption ionisation time-of-ﬂight; MALDI-
ESBLs-E-test
Figure 3: MICs that are >8 fold lower with clavulanate (left) or the
presence of keyhole zones (right) imply ESBL production.
TOF) are being mooted as quicker alternatives to conven-
tional laboratory diagnosis. However, these technologies are
stillrelativelynewindevelopmentandarenotforuseinmost
clinical institutions.
5. Management
With regards to the antimicrobial treatment of the septic
patient, there is a lack of options against ESBL-producing
organisms.
As well as hydrolysing the β-lactam ring found in peni-
cillin, cephalosporins (except cephamycins), and aztreonam,
ESBL producers often have other mechanisms that confer
resistance to other classes of antimicrobials, as described
earlier.
5.1. Carbapenems. Carbapenems are regarded as the antibi-
otic of choice and mainstay against severe infections caused
by ESBLs [3, 15].
They are rapidly bactericidal and demonstrate time-
dependant killing. They are stable against the hydrolytic
activity of the enzyme and although most eﬀect has been
shown in in vitro studies, there is certainly enough data to
support its clinical eﬃcacy [51–53].
Theyalsohavetheaddedbeneﬁtofbeingeﬀectiveagainst
other classes of β-lactamases such as the Amp C class. In the
UK, Imipenem, Meropenem, and Ertapenem are the major
drugs available in this class and generally have equal eﬃcacy
a g a i n s tm o s tb a c t e r i a[ 54, 55]. However, there is some data
to suggest Ertapenem is more susceptible to resistance than
the other two [56]. Doripenem, is a newer carbapenem and
islicensedforuseinseveralcountries(including Japan,USA,
and in Europe) for treatment of severe bacterial sepsis. Like
the other carbapenems, it is stable against ESBL producing
organisms and is considered to have greater eﬃcacy against
Pseudomonas aeruginosa [57].
Resistance to carbapenems has been seen in some strains
of Klebsiella and E. coli species, in the form of carbapen-
emases (Klebsiella producing carbapenemases (KPC) and
New Delhi metallo-β-lactamases (NDM)) and there is an
increasing concern on the overreliance on carbapenem
therapy [52, 58–60].
5.2. Fluoroquinolones.If the ESBL producing organism is sen-
sitive to ciproﬂoxacin in vitro, a good clinical outcome can
be achieved using quinolones [58]. In UTIs caused by sus-
ceptible ESBLs, quinolones may be regarded as an excellent
treatment option [2].6 Critical Care Research and Practice
However, the empirical use of ﬂuoroquinolones to treat
these infections is generally not recommended, due to the
concernofresistance,theratesofwhichareincreasingworld-
wide [58]. This is particularly the case in serious infections.
Two large studies compared the eﬃcacy of carbapenems
over quinolones in treating K. pneumoniae bacteraemia.
One favoured carbapenems and the other found equivalent
eﬃcacy [61, 62].
5.3. Aminoglycosides. As per the quinolones, if an organism
is susceptible on antibiotic testing to aminoglycosides, they
are eﬀective. Aminoglycosides can be a useful adjunct due
their rapidly bactericidal activity; however, their use as
monotherapy should be avoided where possible particularly
in serious infection [63].
5.4. Fosfomycin. Fosfomycin has excellent in vitro activity
against ESBL-producing Enterobacteriaceae [64].
It is one of the few antibiotics active against ESBLs that
can be administered orally. It has been proven eﬀective agai-
nst susceptible ESBL producing isolates causing cystitis [17].
Workhasalsobeendonelookingatitsusefornonurinary
and gastrointestinal tract infections [65]. This study showed
high cure rates of ∼80%, but it looked at the overall use of
fosfomycin against all bacteria, and the drug was often used
in conjunction with other antibiotics and other management
modalities,forexample,surgery.Withparticularregardtoits
activityagainstESBLproducers,fosfomycinisaviableoption
in urinary tract infections especially as resistance appears to
be low at present [17, 65].
5.5. Tigecycline. Tigecycline is a derivative of minocycline
with a broad spectrum of activity. It has excellent in vitro
activityagainstESBLproducers,especiallyE.coliisolates,but
data reﬂecting clinical outcomes is lacking [66].
A drug safety communication from the FDA in Septem-
ber2010(http://www.fda.gov/Drugs/DrugSafety/ucm224370
.htm) warned against its use against serious infections, in
particularagainstitsuseforHAP/VAP.Thiswasduetoanin-
crease in mortality in Tigecycline treated patients compared
with other antibiotics, possibly due to its bacteriostatic mode
of action.
5.6. Cephalosporins. Generally, cephalosporins are not rec-
ommended treatment for ESBL infections as these enzymes
inactivate the drug even if in vitro antibiotic testing reports
a susceptible organism [67]. Indeed such isolates should
be reported as resistant. Studies have looked at Cefepime
as a potential therapeutic option, but clinical data does
not support its use, with high failure rates and inferiority
compared to carbapenem therapy [67–69].
Relevant clinical data regarding the use of cephamycins
is scarce and there is considerable concern over its eﬃcacy in
this situation, mainly due to coresistance [70].
5.7. β-lactamase Inhibitor Combinations. T h e s ea g e n t sm a y
be active against organisms possessing a single ESBL [2].
Whilst it should never be used for serious infections,
amoxicillin/clavulanatemaybeeﬀectiveincommunityacqu-
ired UTIs caused by susceptible ESBLs [17, 71].
Tazobactam has been shown to be more eﬀective against
CTX-M ESBLs compared with clavulanate whilst both
appear superior to sulbactam against SHV and TEM types
[72, 73].
However, this is rarely useful as genotypic testing is not
performed in clinical laboratories. Again, clinical data on the
use of these drugs against ESBLs is lacking and using these
agents would not be appropriate in serious infections [3, 74].
5.8. Polymixins (Colisitin and Polymixin B). Colistin is often
used to combat multidrug-resistant organisms, in particular
Acinetobacter baumannii and Pseudomonas aeruginosa [75].
It has excellent eﬃcacy against ESBL producers [76]a n d
with the emergence of carbapenem resistant organisms (e.g.,
KPCs),ithasbeenused(albeitrarely)totreatsuchinfections
and curb outbreaks [77].
5.9. Nitrofurantoin. Nitrofurantoin can be eﬀective in unco-
mplicated UTIs caused by ESBL producers [78].
5.10. Temocillin. Temocillin is a derivative of Ticarcillin and
is licensed for use in the UK and Belgium for serious
infections caused by susceptible organisms. It is stable to
β-lactamase action and, therefore, active against all SHV,
TEM,andCTX-MESBLsandAmpCβ-lactamases,makingit
an excellent alternative to carbapenems in sensitive bacteria
[79]. It is well tolerated and appears to have little potential to
select for C. diﬃcile [80, 81].
The major drawbacks of Temocillin is its lack of activity
against Gram-positive organisms, anaerobes, and Pseudomo-
nas aeruginosa [82, 83].
However,inthebattleagainstESBL-producinginfections
there is compelling evidence to suggest that Temocillin is an
extremely useful agent [79]. As with a lot of the antibiotics
discussed here, clinical outcome data is scanty and dated.
However, the experience from Belgium, where it has been
in clinical use for over 6 years, provides evidence that it is
eﬀective in serious infections, especially hospital acquired
pneumonia, caused by susceptible ESBL producers [79].
6. Infection Control
6.1. Hospital Cases. ESBL producing organisms can spread
easily within the hospital environment. Most commonly, the
transient carriage of organism on the hands of health care
workers are implicated in patient to patient spread [84–86].
Environmental contamination is also a potential source
with sinks, baths, and medical equipment such as broncho-
scopes, blood pressure cuﬀs, and ultrasound gel all being
reported as sources of infection [2].
Small hospital outbreaks tend to be caused by a single
clone and usually occur in high risk areas such as the ICU,
neonatal units and haematology-oncology units [87–89].
Largeoutbreaksusuallyinvolveseveralcirculatingstrains
of organism at one time and aﬀect several areas in a
healthcare setting.
Eﬀective infection control requires a multidisciplinary
approachandtheprinciplesarethesameaswithtacklingany
multidrug resistant organism.Critical Care Research and Practice 7
Preventing spread of such organisms from patient to
patient is the main focus of infection control measures. The
main issues are hand hygiene of healthcare professionals, use
and cleaning of medical equipment, and colonisation of the
environment [2].
Correct hand hygiene and an adequate level of nursing
staﬀ are crucial in order to reduce the risk of spread between
patients. Screening is advocated in patients being admitted
or transferred from other institutions, including nursing and
residential homes [90]. Surveillance of infected and high risk
patients is used to either monitor an outbreak or, preferably,
prevent one. In this case, rectal swabs on selective media are
used [2].
Patients who are infected with such infections should be
nursed in a single room, or cohorting may be necessary if
such isolation facilities are limited [90].
Antimicrobial stewardship is of paramount importance,
especially in this era of increasingly resistant organisms,
coupled with a lack of antimicrobial options. Selection
pressure must be avoided by judicial and prudent use of
antibiotics. In the context of ESBL producers, a variety of
antibiotic classes must be considered a risk for inducing
selective pressure, not just β-lactams and cephalosporins
[88,91]althoughlimitingwidespreaduseofthirdgeneration
cephalosporins has been shown to be eﬀective in limiting
ESBL producers [92]. Some data supports the switch of
cephalosporins to piperacillin/tazobactam to try and curb
the rising rates of such organisms [92, 93].
The danger with this strategy is the emergence of further
drug-resistant organisms.
The use of ﬂuoroquinolones can also select for ESBL
producers, as the gene encoding for resistance for both ESBL
and quinolones are often found on the same mobile DNA
element [28]. This again reinforces the importance of recog-
nising local resistance patterns. An antibiotic policy which
takes this into account and restricts the use of broad spec-
trum agents (especially third-generation cephalosporins) is
well recognised as key [28, 90, 92, 93].
Clearly, treating the infected patient is crucial in limiting
the spread of ESBLs and antibiotic options have been dis-
cussed above. It should be mentioned that the CTX-M type
are increasingly associated with other resistance mechanisms
which further limits options. This has an obvious impact on
community outbreaks [12].
Certain medical procedures increase the risk of infec-
tion by promoting translocation of these organisms form
colonising areas. Gastrointestinal surgery, intubation, and
urinarycatheterisationareallassociatedwiththisoccurrence
[90, 94].
The use of selective decontamination in the infected
patient remains controversial. Although it may be eﬀective
in reducing the risk of spread, resistance (as well as other
adverse eﬀects associated with antibiotics) to therapies used
in this context is a major problem [2, 95].
In an outbreak situation, it is important to establish whe-
thertheinfectioniscausedbythesameclone(oligoclonal)or
by multiple clones (polyclonal) of the organism. Oligoclonal
outbreaks imply horizontal transfer, that is, person-person
spread of the same bacteria, whereas polyclonal outbreaks
maybecausedbyselectiveantibioticpressure[2].Thisuseful
information allows the institute to focus its control measures
appropriately. Molecular analysis by reference laboratories
allows the clones to be identiﬁed.
Therefore, one can look at controlling hospital outbreaks
at both the individual and institutional level.
In dealing with the infected patient, priority must be
given to appropriate and eﬀective antimicrobials, good hand
hygiene, and avoiding unnecessary procedures, including
central venous catheters.
On an institutional level, screening and isolating all
such infected patients with appropriate infection control
practices, restricting use of broad spectrum cephalosporins
across the hospital (i.e., implementing a stricter antimicro-
bial policy) and investigating environmental contamination
are important [96, 97].
6.2. Community Cases. Community outbreaks can produce
diﬀerent challenges. As mentioned, these tend to be CTX-
M producing E. coli, frequently urinary tract infections. One
paper [90] looked at outbreaks of CTX-M producing E. coli
infections in the UK in 2002-2003 and found a variety of
clones, plasmid transmissibility, and phenotypic behaviour,
all of which can impact on any infection control measure. As
well as the traditional strategies described above, the authors
concluded thorough investigation and termination of food
sources (raw meats are commonly implicated), scrutinising
any ongoing environmental risks and screening of high
risk admissions to health care facilities are all important in
preventing spread of community acquired infections.
7. The Future
There is no doubt that ESBL-producing infections are of
grave concern to the medical world. They are associated with
an increased morbidity and mortality and can be diﬃcult
and time consuming to identify. Coupled with the fact that
prevalence rates are rising globally, including in nonhospital
settings, and the dire lack of eﬀective antimicrobial therapy,
the future is tremendously concerning. Urgent work is
required to develop quicker, cost-eﬀective, and reliable
diagnostic tools as well as new eﬀective therapies.
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